Cystatin C and albuminuria as markers of kidney and cardiovascular diseases in obstructive sleep apnoea syndrome (OSAS)

L. Jonczak, A. Nowinski, R. Plywaczewski, D. Korzybski, A. Czyzak-Gradkowska, M. Targowska, D. Górecka, P. Sliwinski (Warsaw, Poland)

Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA II
Session: Metabolic and cardiovascular consequences of OSA II
Session type: Thematic Poster Session
Number: 3868
Disease area: Sleep and breathing disorders

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Jonczak, A. Nowinski, R. Plywaczewski, D. Korzybski, A. Czyzak-Gradkowska, M. Targowska, D. Górecka, P. Sliwinski (Warsaw, Poland). Cystatin C and albuminuria as markers of kidney and cardiovascular diseases in obstructive sleep apnoea syndrome (OSAS). Eur Respir J 2012; 40: Suppl. 56, 3868

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Relations between cystatin C plasma concentration and cardiovascular complications in patients with obstructive sleep apnoea (OSA)
Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I
Year: 2012

Correlations between cardiovascular diseases and diabetes in obstructive sleep apnoea (OSA)
Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I
Year: 2012

Incidence of cardiovascular complications in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA)
Source: Annual Congress 2007 - Sleep apnoea in cardiorespiratory disorders
Year: 2007


Comparison of plasma NT-proBNP level in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA)
Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep
Year: 2008


Metabolic disturbances in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2010 - Clinical aspects of sleep apnoea
Year: 2010

Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA
Year: 2012


Relationship between age and cardiovascular diseases (CVD) in obstructive sleep apnoea (OSA)
Source: Annual Congress 2008 - Weight control and comorbidity in obstructive sleep apnoea
Year: 2008


C-reactive protein (CRP) and prevalence of cardiovascular diseases in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2007 - Sleep apnoea in cardiorespiratory disorders
Year: 2007


Leukocytosis as a marker of chronic inflammation and early cardiovascular risk in patients with obstructive sleep apnea syndrome
Source: Eur Respir J 2007; 30: Suppl. 51, 593s
Year: 2007

Urine albumin excretion (UAE) is predictive of subclinical cardiovascular diseases associated with obstructive sleep apnea syndrome (OSA)
Source: Annual Congress 2007 - Sleep apnoea in cardiorespiratory disorders
Year: 2007


Cystatin C as a marker of cardiovascular diseases in patients with obstructive sleep apnea (OSA) with concomitant diabetes mellitus type 2 (DM2)
Source: Annual Congress 2013 –A metabolic medley: sleep disordered breathing
Year: 2013

BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS)
Source: Eur Respir J 2005; 26: Suppl. 49, 40s
Year: 2005

Adiponectin is not a cardiovascular risk factor in otherwise healthy subjects with obstructive sleep apnea syndrome (OSAS)
Source: Annual Congress 2009 - Cardiovascular complications in obstructive sleep apnoea
Year: 2009

Association between metabolic disturbances and inflammatory markers in obstructive sleep apnea (OSAS) patients
Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea
Year: 2008


Autoantibody against NBL1 in obstructive sleep apnea patients with cardiovascular disease
Source: International Congress 2017 – New insights into the understanding of sleep and the consequences of sleep apnoea
Year: 2017



Masked hypertension and obstructive sleep apnea syndrome (OSAS)
Source: Eur Respir J 2006; 28: Suppl. 50, 416s
Year: 2006

Relationship between plasma NT-proBNP level and cardiovascular complications in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease
Year: 2010

Relationship between NT-proBNP level, echocardiographic parameters and cardiovascular diseases in patients with obstructive sleep apnoea (OSA)
Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA
Year: 2012


Prevalence and characteristics of patients with obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD): “overlap syndrome (OS)”
Source: Virtual Congress 2020 – Prevalence, characteristics and predictors of obstructive sleep apnoea
Year: 2020


The prevalance of cardiovascular disorders in patients with obstructive sleep apnoea syndrome
Source: Eur Respir J 2002; 20: Suppl. 38, 293s
Year: 2002